The syringe of the affected product can become hard to press and “when additional force is applied, while the needle is in the eye, may cause injury to the patient,” the recall notice reads.
The affected lot is Bevacizumab 1.25mg/0.05m 3 lG Injectable is 190212AB. Its beyond-use date is May 13, 2019.
The product was delivered to clinics in eight states, including Pennsylvania, Illinois, Texas, Wisconsin, Kansas, Tennessee, Indiana and Arizona.
AmEx has notified its customers by phone and mail and said it will send replacements.
More articles on pharmacy:
10 hospitals seeking pharmacy leaders
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.